Clinical Features of Dress Syndrome in 42 Patients
Results: Study patients consisted of 18 men (42.9%) and 24 women (57.1%). The most common causative drugs were antibiotics (33.3%) and anticonvulsants (26.2%), followed by antituberculosis drugs (11.9%), allopurinol (7.1%), nonsteroidal anti-inflammatory drugs (NSAIDs) (7.1%), undetermined agents (7.1%), others (7.1%). The latency period ranged from 2 to 60 days, with a mean of 16.6 days. The longest latency period was noted in the antituberculosis drug group, 35.8 6 16.2 days. Atypical lymphocytosis was noted in 16 patients (38.1%), and thrombocytopenia in 7 patients (16.7%). Hepatic involvement was noted in all study patients. Additionally, lung involvement was noted in 2 patients (5.8%), CNS involvement was in 1 patient (2.4%). Systemic corticosteroids were administered to 8 patients (19.0%).
Complete recovery was noted in 40 patients (95.2%). Two patients had poor outcomes; one died due to opportunistic infection secondary to long-term systemic corticosteroids treatment and the other showed prorgressive deterioration of liver damage, although the final outcome is not known. Conclusions: Drugs associated with DRESS syndrome were variable and most frequently included antibiotics and anticonvulsants. DRESS syndrome was more common than generally recognized, and most of patients with this disease showed better clinical out outcome than that has been generally expected. Methods: Cross-sectional analytical study. We reviewed the medical records of patients with hospitalization and primary diagnosis of Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN) from January 1995 to May 2011. Our study variables have been previously described. We describe median (interquartilar range: IR) and percentage. Exact Fisher test, Mann Withney U and binary logistic regression were used. Results: We obtained 51 medical records: 24 male (47.1%), 27 female (53%). Median age was 5 years (IR 2-8). Thirty eight (76%) corresponded to SJS, four (7.8%) to SJS-TEN overposition and nine (15.7%) to TEN. Mortality was seen in 9 patients (17.6%, 6 male [66.8%] and 3 female [33.3%], P . 0.05). Twenty two cases (43%) were attributed to anticonvulsive drugs, twenty (39%) to antibiotics, two (4%) to non-steroid anti-inflammatory drugs, two (4%) to infection, one (2%) to chemotherapeutic drugs, and in two (4%) no trigger factor was identified. Risk factors associated to mortality were: denudation of .30% Body Surface Area (BSA) (7.1% vs 55.6% P , 0.001), concomitant malignancy (0% vs 22.2% P , 0.028), moderate leucopenia (,1,000 cells/mL) (0% vs 33.3%, P , 0.001), leucocytosis (.20,000 cells/mL) (7.3% vs 22.2%, P , 0.001), hypokalemia (,3.5 mEq/L) (5.6% vs 33.3%, P , 0.011), hyperkalemia (.5.0 mEq/L) (5.6% vs 22.2%, P , 0.011). Total bilirrubin concentration .3.6 mg/dL has tendency to associate with mortality, P ¼ 0.08. Six patients (11.7%) were treated with steroids, fifteen (29.4%) with IV human immunoglobulin and one (1.9%) with both drugs, no statistical difference was observed, though the steroid-treated group showed a tendency towards mortality increase. Some variables were not able to analyze due incomplete medical records. Conclusions: Risk factors associated to mortality in patients with SSJ/ TEN identified in this study are: skin denudation .30% BSA, concomitant malignancy, leucopenia, leukocytosis, hypokalemia and hyperkalemia. Total 
